Streetbeat News

Regulatory

SPY

Federal Reserve's Kugler states that inflation measures excluding housing are near 2%, but the overall target is not yet achieved. He believes progress is being made without overshooting inflation, but reaching the 2% target will take more time.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:39 pm

SPY

Federal Reserve's Kugler indicates that the current labor market should not weaken further and suggests a shift in focus towards the employment mandate.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:37 pm

CABA

Cabaletta Bio, Inc. will present new and updated clinical data on its investigational therapy CABA-201 at the ACR Convergence 2024. The therapy is part of ongoing clinical trials in the RESET™ program.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:32 pm

VVPR

VivoPower and Future Automotive Solutions and Technologies are merging to form a $1.13 billion entity headquartered in the UK, aiming to benefit from the UK's $21 billion clean energy investment programs. The UK government is prioritizing green hydrogen sector investments.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:22 pm

FXI

SPY

Vice President Kamala Harris has stated that she will take swift action if China undermines trade rules, particularly concerning steel. This statement could impact trade relations and market sentiment towards Chinese and US markets.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:09 pm

X

Vice President Harris announced plans to offer tax credits to boost investments in steel and iron manufacturing. The initiative aims to prioritize strengthening and retooling factories.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:04 pm

NCNA

NuCana plc (NASDAQ:NCNA) has been granted a new composition-of-matter patent for its anti-cancer agent NUC-7738 by the USPTO. This strengthens its intellectual property portfolio, which includes over 80 patents globally. NUC-7738 is in Phase 2 trials for melanoma treatment.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:03 pm

LLY

NVO

A study suggests that Novo Nordisk's semaglutide, marketed as Ozempic and Wegovy, may reduce opioid overdose risk in diabetic opioid users. This potential new use for semaglutide could address the urgent need for alternative opioid use disorder therapies. Eli Lilly's dulaglutide, marketed as Trulicity, was also part of the study but did not show the same results. Further research is needed to validate these findings.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 7:59 pm

DE

Former President Donald Trump has threatened to impose a 200% tariff on John Deere products if the company shifts production from the U.S. to Mexico. This could negatively impact Deere & Co's stock price and investors, including some members of Congress. The threat has drawn criticism from figures like Mark Cuban, who argue it could harm the company. Deere shares are currently trading at $407.40.

Portfolio Pulse from Chris Katje

September 25, 2024 | 7:54 pm

BGNE

BMY

MRK

The FDA's Oncologic Drugs Advisory Committee is set to discuss the use of PD-1 cancer drugs from Merck, Bristol Myers, and BeiGene for certain gastric cancer patients. The FDA has raised concerns about the efficacy of these drugs for patients with low PD-L1 expression, suggesting that they may not benefit and could face severe side effects.

Portfolio Pulse from Vandana Singh

September 25, 2024 | 7:54 pm